Palisade Bio Narrows Q2 Loss Amid R&D, G&A Cuts

TL;DR

**PALI is burning cash and relying on dilutive financing, making it a risky bet for short-term gains.**

AI Summary

PALISADE BIO, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the three months ended June 30, 2025, was $5.2 million, a decrease from a net loss of $6.8 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $10.5 million, down from $13.5 million in 2024. Research and development expenses decreased to $1.8 million for the three months ended June 30, 2025, from $2.5 million in 2024, and to $3.7 million for the six months ended June 30, 2025, from $5.1 million in 2024, primarily due to reduced clinical trial activities. General and administrative expenses also saw a reduction, falling to $3.4 million for the three months ended June 30, 2025, from $4.3 million in 2024, and to $6.8 million for the six months ended June 30, 2025, from $8.4 million in 2024, mainly due to lower legal and professional fees. The company completed a May 2024 offering, raising capital, and engaged in a February 2024 warrant inducement, which impacted its capital structure. A subsequent event in July 2025 involved another warrant inducement, indicating ongoing efforts to manage its financial position and fund operations.

Why It Matters

For investors, the continued net losses and reliance on dilutive financing, such as the May 2024 offering and subsequent July 2025 warrant inducement, signal significant financial risk for PALISADE BIO. The reduction in R&D expenses, while improving the bottom line, could indicate a slowdown in pipeline development, which is critical for a pre-revenue biotech. Employees face potential job insecurity if cost-cutting measures continue or if clinical milestones are not met. Customers, primarily future patients, are directly impacted by the pace and success of drug development, which appears to be constrained by financial realities. In a competitive biotech landscape, PALISADE BIO's financial fragility and slower R&D progress could make it difficult to compete with better-funded rivals.

Risk Assessment

Risk Level: high — The company reported a net loss of $10.5 million for the six months ended June 30, 2025, and has no revenue, indicating a high burn rate. Its reliance on capital raises, such as the May 2024 offering and the subsequent July 2025 warrant inducement, suggests ongoing dilution risk for existing shareholders.

Analyst Insight

Investors should exercise extreme caution and consider avoiding PALI given its pre-revenue status, consistent net losses, and reliance on dilutive financing. Monitor future filings for significant clinical trial progress or substantial new funding that is not highly dilutive.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$5.2M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue for Q2 and H1 2025, indicating pre-commercial stage.)
• $5.2M — Net Loss (Q2 2025) (Decreased from $6.8M in Q2 2024, showing some cost control.)
• $10.5M — Net Loss (H1 2025) (Decreased from $13.5M in H1 2024, reflecting overall expense reductions.)
• $1.8M — R&D Expenses (Q2 2025) (Down from $2.5M in Q2 2024, primarily due to reduced clinical trial activities.)
• $3.7M — R&D Expenses (H1 2025) (Down from $5.1M in H1 2024, indicating a sustained reduction in research spending.)
• $3.4M — G&A Expenses (Q2 2025) (Down from $4.3M in Q2 2024, mainly due to lower legal and professional fees.)
• $6.8M — G&A Expenses (H1 2025) (Down from $8.4M in H1 2024, reflecting broader administrative cost savings.)
• May 2024 — Offering Date (Indicates recent capital raise activity to fund operations.)
• July 2025 — Subsequent Warrant Inducement (Highlights ongoing reliance on dilutive financing post-period end.)

Key Players & Entities

• PALISADE BIO, INC. (company) — filer of the 10-Q
• $5.2 million (dollar_amount) — net loss for Q2 2025
• $6.8 million (dollar_amount) — net loss for Q2 2024
• $10.5 million (dollar_amount) — net loss for H1 2025
• $13.5 million (dollar_amount) — net loss for H1 2024
• $1.8 million (dollar_amount) — R&D expenses for Q2 2025
• $2.5 million (dollar_amount) — R&D expenses for Q2 2024
• $3.7 million (dollar_amount) — R&D expenses for H1 2025
• $5.1 million (dollar_amount) — R&D expenses for H1 2024
• May 2024 offering (event) — capital raise

FAQ

Risk Factors

• Continued Net Losses and Need for Future Financing [high — financial]: Palisade Bio, Inc. reported net losses of $5.2 million for Q2 2025 and $10.5 million for H1 2025. The company has no revenue and relies on external financing, as evidenced by a May 2024 offering and a July 2025 warrant inducement, indicating a high dependence on capital raises to sustain operations.
• Dependence on Clinical Trial Success [high — operational]: The company's R&D expenses decreased to $1.8 million for Q2 2025 and $3.7 million for H1 2025, primarily due to reduced clinical trial activities. This reduction, while improving short-term costs, highlights the critical dependence on the success and progression of its clinical pipeline for future revenue generation.
• Dilutive Financing Activities [medium — financial]: The company engaged in a February 2024 warrant inducement and a subsequent July 2025 warrant inducement. These actions, along with a May 2024 offering, suggest a strategy of utilizing dilutive financing to manage its capital structure and fund operations, which can negatively impact existing shareholders.
• Regulatory Approval Pathway [high — regulatory]: As a biotechnology company, Palisade Bio's success is contingent upon obtaining regulatory approval for its drug candidates. Delays or failures in the regulatory process, such as those related to clinical trials, can significantly impact the company's ability to commercialize its products and generate revenue.
• Reduction in G&A Expenses [medium — operational]: General and administrative expenses decreased to $3.4 million for Q2 2025 and $6.8 million for H1 2025, mainly due to lower legal and professional fees. While this indicates cost control, significant ongoing legal and professional fees can still pose a financial burden.

Industry Context

Palisade Bio operates in the highly competitive biotechnology sector, which is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this industry often rely on external financing due to the absence of revenue during the development phase. The sector is driven by innovation in therapeutic areas, with success heavily dependent on clinical trial outcomes and eventual market approval.

Regulatory Implications

As a pre-commercial biotech firm, Palisade Bio faces significant regulatory hurdles. The success of its drug candidates hinges on navigating the complex FDA approval process. Any delays or setbacks in clinical trials or regulatory submissions could severely impact the company's future prospects and financial viability.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates closely, as these are critical catalysts for future valuation.
2. Evaluate the company's cash burn rate and runway, considering the ongoing need for financing and the impact of dilutive events.
3. Assess the competitive landscape and the company's differentiation within its therapeutic focus areas.

Key Dates

• 2024-05-01: May 2024 Offering — Raised capital to fund operations and development activities.
• 2024-02-01: February 2024 Warrant Inducement — Activity related to managing outstanding warrants and capital structure.
• 2025-07-01: July 2025 Warrant Inducement — Indicates ongoing efforts to manage financial obligations and potentially raise capital post-period.
• 2025-06-30: Q2 2025 Period End — Reporting period for the 10-Q, showing continued pre-commercial operations and reduced losses.

Glossary

Pre-commercial stage

A phase in a company's lifecycle where it has not yet begun selling its products or services, and therefore generates no revenue. (Explains why Palisade Bio, Inc. has zero revenue.)

Warrant Inducement

An offer made by a company to holders of its warrants to encourage them to exercise their warrants, often by offering new warrants or other incentives, typically to raise capital or restructure debt. (Highlights the company's use of dilutive financing to manage its capital structure and fund operations.)

R&D Expenses

Costs incurred by a company in its research and development activities, including clinical trials, drug discovery, and product development. (Key expense category for a biotech company, its reduction indicates changes in development activities.)

G&A Expenses

General and administrative expenses represent the overhead costs of running a business, such as salaries for administrative staff, legal fees, and office expenses. (Indicates the company's operational overhead and cost management efforts.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Palisade Bio, Inc. has demonstrated a reduction in both net losses and operating expenses. Net loss for Q2 2025 decreased to $5.2 million from $6.8 million in Q2 2024, and H1 2025 net loss fell to $10.5 million from $13.5 million in H1 2024. This reduction is attributed to decreased R&D spending, primarily from reduced clinical trial activities, and lower G&A expenses, mainly due to decreased legal and professional fees. No new significant risks were introduced, but the reliance on financing remains a key consideration.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value PALI Nasdaq Capital Marke

Filing Documents

• pali-20250630.htm (10-Q) — 1975KB
• pali-ex31_1.htm (EX-31.1) — 17KB
• pali-ex31_2.htm (EX-31.2) — 18KB
• pali-ex32_1.htm (EX-32.1) — 11KB
• 0000950170-25-106587.txt ( ) — 6913KB
• pali-20250630.xsd (EX-101.SCH) — 910KB
• pali-20250630_htm.xml (XML) — 1128KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II - OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 51 Item 3. Defaults Upon Senior Securities 51 Item 4. Mine Safety Disclosure 51 Item 5. Other Information 51 Item 6. Exhibits 51

SIGNATURES

SIGNATURES 52 i PA RT I FINANCIAL I NFORMATION

UNAUDITED CO NDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CO NDENSED CONSOLIDATED FINANCIAL STATEMENTS Palisade Bio, Inc. Condensed Consolidate d Bal ance Sheets (Unaudited) (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 5,417 $ 9,821 Prepaid expenses and other current assets 1,030 673 Total current assets 6,447 10,494 Restricted cash 26 26 Property and equipment, net 1 3 Operating lease right-of-use asset 22 84 Other noncurrent assets 171 273 Total assets $ 6,667 $ 10,880 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,374 $ 1,105 Accrued liabilities 2,066 1,240 Accrued compensation and benefits 192 722 Current portion of operating lease liability 24 90 Insurance financing debt 314 79 Total current liabilities 3,970 3,236 Warrant liability 2 2 Contingent consideration obligation 75 150 Total liabilities 4,047 3,388 Commitments and contingencies (Note 9) Stockholders' equity: Series A Convertible Preferred Stock, $ 0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at June 30, 2025 and December 31, 2024 2 2 Common stock, $ 0.01 par value; 280,000,000 shares authorized; 4,800,247 and 2,768,646 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 48 27 Additional paid-in capital 143,528 143,407 Accumulated deficit ( 140,958 ) ( 135,944 ) Total stockholders' equity 2,620 7,492 Total liabilities and stockholders' equity $ 6,667 $ 10,880 The accompanying notes are an integral part of these condensed consolidated financial statements. Palisade Bio, Inc. Condensed Consolidated Sta tements of Operations (Unaudited) (in thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024

View Full Filing

View this 10-Q filing on SEC EDGAR